Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VTRS

Viatris Inc

Dec 01 • 04:00PM ET

9.37

Dollar change +0.19
Percentage change 2.07	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	S&P 500	P/E	6.21	EPS (ttm)	1.51	Insider Own	1.95%	Shs Outstand	1.21B	Perf Week	-0.64%
Market Cap	11.24B	Forward P/E	3.35	EPS next Y	2.79	Insider Trans	-0.06%	Shs Float	1.18B	Perf Month	5.04%
Income	1.83B	PEG	-	EPS next Q	0.65	Inst Own	78.51%	Short Float / Ratio	2.47% / 3.23	Perf Quarter	-13.16%
Sales	15.42B	P/S	0.73	EPS this Y	-11.59%	Inst Trans	2.15%	Short Interest	29.10M	Perf Half Y	0.43%
Book/sh	17.09	P/B	0.55	EPS next Y	-5.65%	ROA	3.76%	Target Price	11.41	Perf Year	-15.05%
Cash/sh	1.16	P/C	8.08	EPS next 5Y	-2.50%	ROE	9.15%	52W Range	8.74 - 12.40	Perf YTD	-15.81%
Dividend	0.48	P/FCF	5.36	EPS past 5Y	5.60%	ROI	4.81%	52W High	-24.43%	Beta	1.14
Dividend %	5.12%	Quick Ratio	1.06	Sales past 5Y	8.11%	Gross Margin	41.35%	52W Low	7.21%	ATR	0.21
Employees	37000	Current Ratio	1.60	Sales Q/Q	-2.96%	Oper. Margin	13.43%	RSI (14)	52.97	Volatility	2.00% 2.28%
Optionable	Yes	Debt/Eq	0.89	EPS Q/Q	-5.60%	Profit Margin	11.88%	Rel Volume	0.82	Prev Close	9.18
Shortable	Yes	LT Debt/Eq	0.83	Earnings	Nov 07 AMC	Payout	28.11%	Avg Volume	9.02M	Price	9.37
Recom	2.82	SMA20	1.51%	SMA50	0.22%	SMA200	-5.36%	Volume	7,425,894	Change	2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24
Mar-08-21	Downgrade	Goldman	Buy → Neutral	$20 → $15
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral	$21 → $18
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$17
Jan-05-21	Initiated	Argus	Hold
Dec-14-20	Initiated	Bernstein	Mkt Perform	$21

Show Previous Ratings

Nov-24-23 08:16PM	Insider Sell Alert: President, Greater China Xiangyang Ni Sells 14,937 Shares of Viatris Inc (VTRS) (GuruFocus.com)
Nov-22-23 06:38AM	Viatris partnered ulcerative colitis drug fails interim phase 3 review, sending InDex's stock down 60% (FierceBiotech.com)
Nov-21-23 06:00PM	Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care (ACCESSWIRE)
05:09AM	Viatris Inc's Dividend Analysis (GuruFocus.com)
Nov-20-23 06:30AM	7 Low P/E Stocks Poised to Rebound (InvestorPlace)
03:00PM	Loading…
Nov-17-23 03:00PM	Top 30 Lowest P/E Ratios of the S&P 500 (Insider Monkey)
11:32AM	Why the Cheapest Stock in the S&P 500 Is No Bargain (Barrons.com)
Nov-14-23 08:00AM	Viatris to Participate in the Jefferies London Healthcare Conference (PR Newswire)
Nov-13-23 08:00AM	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
Nov-10-23 09:30AM	Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
Nov-09-23 03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
12:18AM	The Viatris Inc (VTRS) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-08-23 03:36PM	Viatris Inc. (NASDAQ:VTRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:17PM	Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip (Zacks)
10:34AM	Analyst Report: Viatris Inc. (Morningstar Research)
05:25PM	Loading…
Nov-07-23 05:25PM	Viatris (VTRS) Beats Q3 Earnings Estimates (Zacks)
04:27PM	Viatris: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] (PR Newswire)
Nov-06-23 10:47AM	Should You Buy Viatris (VTRS) Ahead of Earnings? (Zacks)
Nov-05-23 01:27AM	Is Viatris (VTRS) a Smart Long-Term Pick? (Insider Monkey)
Oct-31-23 11:17AM	Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store? (Zacks)
10:01AM	Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
05:05AM	Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors? (Motley Fool)
Oct-30-23 04:35PM	13 Most Undervalued Pharma Stocks To Buy According To Analysts (Insider Monkey)
04:30PM	Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance (ACCESSWIRE)
12:10PM	Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again (Zacks)
09:00AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-29-23 05:35PM	14 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds (Insider Monkey)
Oct-27-23 08:45AM	Viatris Named to 3BLs 100 Best Corporate Citizens of 2023 Ranking (ACCESSWIRE)
Oct-25-23 04:00PM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row (ACCESSWIRE)
02:44PM	Loading…
Oct-24-23 02:44PM	Bill Miller Portfolio: 12 Picks From Legendary Value Investor (Insider Monkey)
11:02AM	12 Defensive Healthcare Dividend Stocks To Invest In (Insider Monkey)
Oct-23-23 12:52PM	Markets Turn Positive at Midday After 10-Year Treasury Yield Reverses Course (Investopedia)
09:00AM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row (PR Newswire)
Oct-20-23 05:00PM	Rajiv Malik to Retire as President of Viatris Effective April 1, 2024 (PR Newswire)
Oct-18-23 08:00AM	Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking (PR Newswire)
Oct-13-23 09:15AM	Viatris Just Sold Off 3 Key Segments. Is It Still a Buy? (Motley Fool)
Oct-10-23 09:29AM	Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023 (PR Newswire)
Oct-08-23 09:45AM	2 Top Value Stocks to Buy in October (Motley Fool)
08:15AM	2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip (Motley Fool)
Oct-03-23 12:28PM	Viatris (VTRS) to Divest Some More Businesses, Shares Gain (Zacks)
Oct-02-23 04:54PM	US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic (Reuters)
04:31PM	Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion (Investor's Business Daily)
03:58PM	Analyst Report: Viatris Inc. (Morningstar Research)
11:33AM	Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Oct-01-23 06:01PM	UPDATE 2-Drugmaker Viatris to divest some businesses for $3.6 bln (Reuters)
05:16PM	Drugmaker Viatris to divest some of its businesses (Reuters)
05:00PM	Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA (PR Newswire)
Sep-30-23 07:58AM	Could Viatris Stock Help You Become a Millionaire? (Motley Fool)
Sep-28-23 10:48AM	Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent (Zacks)
Sep-27-23 08:00AM	Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (PR Newswire)
08:00AM	Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents (GlobeNewswire)
Sep-14-23 09:18AM	Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks (Motley Fool)
Sep-12-23 04:00PM	Viatris Named to TIME's Worlds Best Companies 2023 List (ACCESSWIRE)
Sep-09-23 07:20AM	3 Pharmaceutical Stocks That Are Too Cheap to Ignore (Motley Fool)
Sep-07-23 07:17PM	Analyst Report: Viatris Inc. (Morningstar Research)
Sep-06-23 12:33PM	Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
12:03PM	Unraveling the Future of Viatris Inc (VTRS): A Deep Dive into Key Metrics (GuruFocus.com)
11:30AM	Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report? (Zacks)
Sep-05-23 10:36AM	Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids (Zacks)
05:00AM	Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV (PR Newswire)
Sep-01-23 08:30AM	CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know (Motley Fool)
Aug-31-23 08:45AM	Viatris Stock: Bear vs. Bull (Motley Fool)
Aug-30-23 09:55AM	Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-24-23 05:00PM	Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris (Motley Fool)
Aug-23-23 12:06PM	Unraveling Viatris Inc's Potential Underperformance: A Deep Dive into the GF Score (GuruFocus.com)
Aug-18-23 07:45AM	Where Will Viatris Be in 5 Years? (Motley Fool)
Aug-16-23 11:06AM	Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy? (Motley Fool)
Aug-11-23 10:00AM	2 Beaten-Down Dividend Stocks to Buy (Motley Fool)
08:25AM	If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today (Motley Fool)
Aug-10-23 09:30AM	Viatris Has Been Bearish for One Reason But Is Still an Intriguing Value Play (TheStreet.com)
06:08AM	Viatris Inc. (NASDAQ:VTRS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 09:37AM	Is Viatris Stock Good for Dividend Income? (Motley Fool)
07:22AM	Analyst Report: Viatris Inc (Argus Research)
07:07AM	Market Digest: ACM, ALL, BIIB, CMCSA, GT, J, SWKS, VFC, VTRS (Argus Research)
Aug-08-23 09:54AM	Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss (Zacks)
09:42AM	Company News for Aug 8, 2023 (Zacks)
Aug-07-23 10:55PM	Q2 2023 Viatris Inc Earnings Call (Thomson Reuters StreetEvents)
09:00PM	Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
07:11PM	Analyst Report: Viatris Inc. (Morningstar Research)
05:14PM	S&P 500 Gains and Losses Today: Stocks Take Off After Earnings Reports (Investopedia)
03:37PM	Viatris Shares Gain on Sales, Divestitures, and FDA Review of Its MS Drug (Investopedia)
12:59PM	Markets Mixed at Midday on New Earnings Reports, Upcoming Data (Investopedia)
12:59PM	Markets Higher at Midday on New Earnings Reports, Upcoming Data (Investopedia)
12:35PM	Viatris to announce at least one divestiture in 3Q (American City Business Journals)
12:33PM	Is Viatris Inc. (VTRS) Modestly Overvalued? (GuruFocus.com)
12:08PM	Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows (Zacks)
08:15AM	Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates (Zacks)
07:11AM	Viatris: Q2 Earnings Snapshot (AP Finance)
06:59AM	Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] (PR Newswire)
06:54AM	Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis (PR Newswire)
Aug-04-23 08:20AM	Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years (Motley Fool)
Jul-31-23 11:45AM	Viatris (VTRS) to Report Q2 Earnings: What's in the Offing? (Zacks)
06:59AM	Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva (PR Newswire)
Jul-22-23 06:00AM	Viatris Stock: Bull vs. Bear (Motley Fool)
Jul-20-23 09:20AM	1 Reason I Wouldn't Buy This High-Yielding Dividend Stock (Motley Fool)
Jul-19-23 02:00PM	Better Pharma Buy: Viatris vs. Pfizer (Motley Fool)
08:18AM	12 Best NASDAQ Stocks Under $50 (Insider Monkey)
Jul-15-23 05:00PM	Better High-Yield Dividend Stock: Altria or Viatris? (Motley Fool)
Jul-14-23 07:45AM	3 Reasons to Buy Viatris Stock, and 1 Reason to Sell (Motley Fool)

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ni Xiangyang (Sean)	President, Greater China	Nov 24	Sale	9.37	14,937	139,942	64,658	Nov 24 06:00 PM
Ni Xiangyang (Sean)	President, Greater China	Nov 23	Option Exercise	0.00	33,179	0	79,595	Nov 24 06:00 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 06	Sale	11.08	3,148	34,891	46,416	Mar 06 07:01 PM
Cuneo Andrew	See Remarks	Mar 04	Option Exercise	0.00	6,518	0	53,460	Mar 06 07:00 PM
Roman Brian	Global General Counsel	Mar 04	Option Exercise	0.00	17,774	0	96,585	Mar 06 07:00 PM
CORNWELL W DON	Director	Mar 04	Option Exercise	0.00	20,313	0	42,510	Mar 06 07:01 PM
MARK RICHARD A	Director	Mar 04	Option Exercise	0.00	20,313	0	53,478	Mar 06 07:01 PM
HIGGINS MELINA E	Director	Mar 04	Option Exercise	0.00	20,313	0	83,381	Mar 06 07:01 PM
KILTS JAMES M	Director	Mar 04	Option Exercise	0.00	20,313	0	98,590	Mar 06 07:01 PM
van der Meer Mohr Pauline	Director	Mar 04	Option Exercise	0.00	20,313	0	40,267	Mar 06 07:00 PM
GOETTLER MICHAEL	Chief Executive Officer	Mar 04	Option Exercise	0.00	107,827	0	365,119	Mar 06 07:00 PM
Lyons Dillon JoEllen	Director	Mar 04	Option Exercise	0.00	20,313	0	59,859	Mar 06 07:01 PM
COURY ROBERT J	Executive Chairman	Mar 04	Option Exercise	0.00	127,970	0	1,236,952	Mar 06 07:01 PM
Campbell Paul	See Remarks	Mar 04	Option Exercise	0.00	18,515	0	113,538	Mar 06 07:01 PM
KORMAN HARRY	Director	Mar 04	Option Exercise	0.00	20,313	0	70,951	Mar 06 07:00 PM
Narula Sanjeev	Chief Financial Officer	Mar 04	Option Exercise	0.00	40,287	0	89,996	Mar 06 07:00 PM
Mauro Anthony	See Remarks	Mar 04	Option Exercise	0.00	37,917	0	355,502	Mar 06 07:00 PM
PARRISH MARK W	Director	Mar 04	Option Exercise	0.00	20,313	0	102,563	Mar 06 07:00 PM
Malik Rajiv	President	Mar 04	Option Exercise	0.00	85,314	0	685,631	Mar 06 07:00 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 04	Option Exercise	0.00	7,835	0	49,564	Mar 06 07:01 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 03	Sale	11.18	3,093	34,579	41,729	Mar 06 07:01 PM
Campbell Paul	See Remarks	Mar 02	Option Exercise	0.00	47,712	0	101,172	Mar 06 07:01 PM
COURY ROBERT J	Executive Chairman	Mar 02	Option Exercise	0.00	108,739	0	1,162,429	Mar 06 07:01 PM
GOETTLER MICHAEL	Chief Executive Officer	Mar 02	Option Exercise	0.00	91,623	0	294,432	Mar 06 07:00 PM
Roman Brian	Global General Counsel	Mar 02	Option Exercise	0.00	14,096	0	84,567	Mar 06 07:00 PM
Cuneo Andrew	See Remarks	Mar 02	Option Exercise	0.00	7,929	0	50,105	Mar 06 07:00 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 02	Option Exercise	0.00	7,765	0	44,822	Mar 06 07:01 PM
Malik Rajiv	President	Mar 02	Option Exercise	0.00	322,494	0	648,123	Mar 06 07:00 PM
Mauro Anthony	See Remarks	Mar 02	Option Exercise	0.00	148,163	0	340,490	Mar 06 07:00 PM
Narula Sanjeev	Chief Financial Officer	Mar 02	Option Exercise	0.00	28,192	0	61,299	Mar 06 07:00 PM
Ni Xiangyang (Sean)	President, Greater China	Feb 28	Sale	11.22	5,250	58,893	37,057	Mar 01 07:01 PM
Ni Xiangyang (Sean)	President, Greater China	Feb 27	Option Exercise	0.00	13,142	0	42,307	Mar 01 07:01 PM
GOETTLER MICHAEL	Chief Executive Officer	Feb 27	Option Exercise	0.00	128,728	0	257,130	Mar 01 07:04 PM
Narula Sanjeev	Chief Financial Officer	Feb 27	Option Exercise	0.00	22,796	0	43,624	Mar 01 07:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTRS

Viatris Inc

Upgrade your FINVIZ experience